Specialty Pharmacy

Hepatitis C infection causes more deaths than HIV, hepatitis B, and tuberculosis combined.

UnitedHealth is the only company to announce it may depart from insurance exchanges.

The $750 per pill price of pyrimethamine could soon be undercut by a new compound selling for $1 per pill.

Pharmacy leaflets hold much potential for helping patients properly assess the risks and benefits of their medications.

Research finds patients are not staying on methotrexate long enough before switching to more costly biologic drugs.

Catch up with any news you missed last month.

A new study shows that adding a third drug to the ingredients in Harvoni could cure hepatitis C in half the ordinary time.

In California, a class action lawsuit has been filed on behalf of thousands of Blue Cross beneficiaries living with hepatitis C who were denied treatment.

Largest carriers increased rates by 23.9%, compared with a 13.7% jump by other carriers.

Shifts in sleep schedules may increase an individual's risk for diabetes.

Qualgen has taken corrective actions concerning its compounding facility conditions and sterility processes.

Empliciti combination decreased disease progression risk by 30%.

Reolysin plus bortezomib and dexamethasone treats patients with relapsed or refractory multiple myeloma.

David D'Altorio, PharmD, senior vice president of health services at MedImpact Healthcare Systems, discusses developments affecting the specialty landscape.

Top articles from the leading specialty pharmacy journal.

Treating chronic pulmonary obstructive disease with both inhaled corticosteroids and long-acting bronchodilators remains controversial, but new evidence suggests that this controller combination could reduce mortality risk.

Patients who received golimumab and methotrexate reported larger improvements than monotherapy patients.

When the virus enters the nervous system it can affect attention, memory, and language.

Janssen Research and Development LLC has submitted a new drug application to the FDA for canagliflozin and metformin hydrochloride extended release (Invokamet XR).

Experimental personalized peptide cancer vaccine found to extend overall survival.

Top recent news in cancer drug development.

MS drug previously refused market authorization because of cancer concerns.

Therapeutic vaccine may reduce cervical cancer by fighting disease after infection.

One-step test will screen, detect and confirm a hepatitis C virus infection.

Tofacitinib effective in the treatment of moderate to severe atopic dermatitis.

Synthetic estrogen molecule may have a profound effect on the ability to survive major blood loss.

Top stories of the week on Specialty Pharmacy Times.

Near-fatal car accident leads man down long journey from infection to cure for hepatitis C.